BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu W, Quan B, Lu S, Tang B, Li M, Chen R, Ren Z, Yin X. First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. Front Oncol 2021;11:771045. [PMID: 35004289 DOI: 10.3389/fonc.2021.771045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Qiao Y, Zhou M, Guo J, Lin Y, Li W, An C, Li C. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. Cancer Med 2023;12:5436-49. [PMID: 36254376 DOI: 10.1002/cam4.5366] [Reference Citation Analysis]
2 Sun L, Wang H, Liu Q, Meng F, Zhang J, Li X, Chang S, Li G, Chen F. Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma. Oncol Rep 2023;49:55. [PMID: 36734286 DOI: 10.3892/or.2023.8492] [Reference Citation Analysis]
3 Lima HA, Alaimo L, Brown ZJ, Endo Y, Moazzam Z, Tsilimigras DI, Shaikh C, Resende V, Guglielmi A, Ratti F, Aldrighetti L, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Hugh T, Endo I, Shen F, Pawlik TM. Application of hazard functions to investigate recurrence after curative-intent resection for hepatocellular carcinoma. HPB (Oxford) 2023;25:260-8. [PMID: 36470717 DOI: 10.1016/j.hpb.2022.11.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bracchiglione J, Rodríguez-Grijalva G, Requeijo C, Santero M, Salazar J, Salas-Gama K, Meade AG, Antequera A, Auladell-Rispau A, Quintana MJ, Solà I, Urrútia G, Acosta-Dighero R, Bonfill Cosp X. Systemic Oncological Treatments versus Supportive Care for Patients with Advanced Hepatobiliary Cancers: An Overview of Systematic Reviews. Cancers (Basel) 2023;15. [PMID: 36765723 DOI: 10.3390/cancers15030766] [Reference Citation Analysis]
5 Liu K, Zhu Y, Zhu H. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis. Front Immunol 2022;13:1103055. [PMID: 36713376 DOI: 10.3389/fimmu.2022.1103055] [Reference Citation Analysis]
6 Wang L, Yan D, Shen L, Xie Y, Yan S. Prognostic Value of a CT Radiomics-Based Nomogram for the Overall Survival of Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy. J Oncol 2023;2023:1554599. [PMID: 36636027 DOI: 10.1155/2023/1554599] [Reference Citation Analysis]
7 wang L, Peng Y, Qin S, Wan X, Zeng X, Li S, Liu Q, Tan C. First-Line Systemic Treatment Strategies for unresectable hepatocellular carcinoma : a cost-effectiveness analysis.. [DOI: 10.1101/2022.12.15.22283549] [Reference Citation Analysis]
8 Sun L, Xu X, Meng F, Liu Q, Wang H, Li X, Li G, Chen F. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Front Oncol 2022;12:980214. [DOI: 10.3389/fonc.2022.980214] [Reference Citation Analysis]
9 Sauzeau V, Beignet J, Vergoten G, Bailly C. Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma. Pharmacol Res 2022;:106220. [PMID: 35405309 DOI: 10.1016/j.phrs.2022.106220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]